Goldman Sachs analyst Rajan Sharma upgraded Immunocore to Buy from Neutral with a price target of $80, up from $33. The analyst’s view reflects the approval and strong commercial launch of Kimmtrak, while also now including the additional revenue opportunity in cutaneous melanoma and having gained more visibility on the pipeline beyond Kimmtrak.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore is awarded the Prix Galien France award for KIMMTRAK
- Immunocore presents ovarian cancer expansion data for IMC-C103C
- Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
- Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
- Immunocore, Gadeta announce agreement to develop gamma delta TCR ImmTAC
